Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott's FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice for pump users and enabling 15-day sensors with minute-by-minute glucose data. This integration pairs Tandem's advanced AutoBolus-enabled AID algorithm with one of Europe's most widely used CGM platforms, potentially broadening its addressable user base and deepening product stickiness in key European markets. The move supports the company's near-term interoperability and international growth catalyst, though it does not fundamentally change execution risk around commercial transformation or pressure from new entrants in the U.S. pump market. Tandem's narrative projects $1.4 billion revenue and $63.4 million earnings by 2029, requiring 10.3% yearly revenue growth and an earnings increase of about $158 million from a current loss of $94.5 million.
Tandem Diabetes Care IncTandem's t:slim X2 pump now integrates with Abbott's widely used CGM in five European markets, broadening its addressable user base and increasing product stickiness.
Abbott LaboratoriesAbbott's FreeStyle Libre 3 Plus CGM is integrated with Tandem's pump, expanding its use in five European markets.